# Advances in Clinical Medical Research and Healthcare Delivery

#### Volume 1 | Issue 3

Article 12

#### 2021

# The Challenge of Preventing a Rare but Potentially Devastating latrogenic Exposure to Variant Creutzfeldt-Jakob Disease: An Ambi-directional Observation with Policy Intervention

**Ritambhara Pandey** Ritambhara.Pandey@rochesterregional.org Devesh Rai Devesh.Rai@rochesterregional.org Julie Giles Julie.Giles@rochesterregional.org MaryRose Laguio-Vila Rochester Regional Health System, maryrose.laguiovila@rochesterregional.org Emil Lesho

Rochester Regional Health System, carolinelesho@yahoo.com

Follow this and additional works at: https://scholar.rochesterregional.org/advances



Part of the Infectious Disease Commons



This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License

#### **Recommended Citation**

Pandey R, Rai D, Giles J, Laguio-Vila M, Lesho E. The Challenge of Preventing a Rare but Potentially Devastating latrogenic Exposure to Variant Creutzfeldt-Jakob Disease: An Ambi-directional Observation with Policy Intervention. Advances in Clinical Medical Research and Healthcare Delivery. 2021; 1(3). doi: 10.53785/2769-2779.1032.

#### ISSN: 2769-2779

This Article is brought to you for free and open access by RocScholar. It has been accepted for inclusion in Advances in Clinical Medical Research and Healthcare Delivery by an authorized editor of RocScholar. For more information, please contact Advances@rochesterregional.org.

# The Challenge of Preventing a Rare but Potentially Devastating latrogenic Exposure to Variant Creutzfeldt-Jakob Disease: An Ambi-directional Observation with Policy Intervention

### Abstract

Although rare, patients with variant Creutzfeldt-Jakob Disease (vCJD) in their differential diagnosis of progressive dementia and movement disorder could continue to present to hospitals for care. However, U.S.-based infection control guidelines do not fully address the possibility of vCJD. After near-misses involving increasing numbers of patients with clinical findings and epidemiologic risks compatible with vCJD, or exposures to chronic wasting disease, we sought to improve recognition and prevention of iatrogenic spread of these prion-related diseases.

#### Keywords

variant Creutzfeldt-Jakob Disease, chronic wasting disease, disinfection and sterilization, equipment reprocessing

### **Creative Commons License**



This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License

#### Introduction

Transmissible spongiform encephalopathies (TSEs) are progressively fatal neurodegenerative diseases caused by infectious, misshapen prion proteins (PrP<sup>Sc</sup>). In humans, they include variant and classic (or sporadic) Creutzfeldt-Jakob Disease (vCJD/sCJD), the latter being far more common in the U.S. TSEs present substantial diagnostic, infection control, and patient notification challenges. (Table 1). For example, because prions resist usual standard disinfection and sterilization protocols, iatrogenic exposures can occur via contaminated instruments or equipment. Iatrogenic TSE can also be transmitted by percutaneous exposure to certain types of tissue (mostly neural for sCJD), while vCJD can also be transmitted by exposure to infected lymphoid tissue and possibly blood transfusions. This is why people from regions where TSE was prevalent were precluded from donating blood.<sup>1-3</sup>

However, U.S.-based cleaning and disinfection and control guidelines and updates do not address the possibility of vCJD.<sup>4, 5</sup> Those guidelines do, however, recommend heightened awareness and policy modification as events dictate.<sup>4, 5</sup> Additionally, experts have noted persistent risk of TSEs other than sCJD in unsuspected geographic locations and a need for heightened suspicion and surveillance.<sup>6, 7</sup> Furthermore, surveys of lymphoid tissue where PrP<sup>sc</sup> is found in cases of vCJD, suggest the prevalence of asymptomatic disease can be as high as 1 in 2,000 in persons born between 1941 and 1985.<sup>8</sup>

#### **Two Illustrative Incidents**

Two incidents typified the challenges we faced in caring for these and similar patients and provided the impetus for this approach. The first incident involved a patient who presented with memory problems, apathy and depression leading to job loss. These symptoms were followed by confusion, impaired gait, occasional jerking movements and eventually dementia. The patient lived in England and France from 1985 to 1993 and ate canned dog food occasionally. The patient also required urgent pelvic and abdominal surgery immediately after admission. MRI showed restricted diffusion in the frontal, parietal, and occipital cortexes. 14-3-3, and Tau protein were negative. Since immune mediated encephalitis was also a leading consideration on the list of possible diagnoses, the patient underwent plasma exchange. Then, 13 days later, the real-time quaking induced conversion (RT-QuIC) result became available and was positive. Contact tracing revealed that in the meantime, three other patients had undergone pheresis on the same machine. The Red Cross was contacted and recommended decommissioning the machine until further notice. The dilemma of patient notification was debated by the ethics, risk management, infection control team and the hospital leaders.

The second incident involved a middle-aged patient who presented with psychiatric symptoms and cognitive decline. The patient, who was an avid hunter and consumed venison and squirrel brains, also developed impaired gait. An MRI showed bilateral pulvinar signs. The EEG did not reveal periodic sharp waves, but showed nonspecific abnormalities including intermittent rhythmic delta activity. The patient required several diagnostic and therapeutic procedures including endoscopies and endotracheal intubation that entailed exposure to lymphoid tissue. Approximately two weeks after admission, 14-3-3, Tau protein, and RT-QuIC results became available and were positive, creating a dilemma for reprocessing critical and semi-critical equipment. After several months in the hospital, the patient was discharged to a long-term care facility, and died more than 11 months after symptom onset. vCJD could not be definitively excluded until autopsy results became available several months later and revealed sCJD. Table 1 highlights some of the challenges associated with TSE.

Table 1: Diagnostic, Infection Control, and Notification Challenges Associated with				
Transmissible Spongiform Encephalopathies				
Diagnostic Challenge				
A. Most clinicians are unfamiliar with TSEs due to the rarity of those diseases.				
B. vCJD and CJD can be hard to distinguish clinically.				
C. No gold standard laboratory test exists for differentiating types of TSEs.				
D. Turn-around-time for RT-QuIC can be up to 14 days or longer.				
E. In some cases, definitive diagnosis requires brain biopsy or only becomes available after autopsy.				
F. The National Prion Center typically only releases autopsy results to public health				
departments, furthering delay.				
Infection Control Challenges				
A. Prions resist usual disinfection and sterilization methods.				
B. US-based disinfection and sterilization guidelines do not address possibility of vCJD				
contaminated equipment.				
Notification Challenges or Considerations				
A. Should potentially exposed patients be informed given the below considerations?				
i. Potential negative impact of informing patients about a fatal, untreatable				
brain disease.				
ii. No effective screening test is available for TSE.				
iii. No post exposure prophylaxis is available.				
iv. Contaminated instruments often become mixed during re-processing making				
identification and linkage to specific patients nearly impossible.				
v. Autoclaving is generally superior to chemical reprocessing for prions.				
vi. If equipment was re-processed more than twice, prions would be less likely to				
survive.				

Against this backdrop, we sought to enhance our efforts to detect and prevent iatrogenic spread of TSE, including vCJD. We also aimed to increase awareness among all providers, prevent over-reaction or unnecessarily discarding expensive equipment, while simultaneously not missing an opportunity to prevent avoidable exposures.

## Setting

The health system consists of 8 hospitals and 9 urgent care centers in St Lawrence County, and the 9 counties comprising the Finger Lakes region of NY. The system serves diverse populations including refugee communities and permanent or temporarily relocated citizens or expatriates from many countries.

## Methods

The study consisted of a four-year ambi-directional observation of patients with suspected or confirmed CJD, with a two-component intervention at the midpoint (01/01/2017). Patients who had a laboratory order for 14-3-3 or RT-QuIC were included. The first part of the intervention entailed an educational campaign nearly identical to the one successfully used for device-related infections and described previously.<sup>9</sup> The second part of the intervention involved extensive

revision of our existing CJD policy, incorporating guidelines from the UK Department of Health and Social Care Advisory Committee and the World Health Organization regarding vCJD.<sup>10, 11</sup>

Briefly, the educational campaign included one-on-one engagements between infection preventionists (IPs), the hospital epidemiologist, the neurologist champion and frontline nurses and providers. Modes of delivery included individual face-to-face meetings, team huddles, committee meetings, group lectures and grand rounds. Relevant guidelines were posted on hospital websites and intranet.

The policy and attendant protocols were revised based on input from the neurology, laboratory and sterile processing departments One goal of the policy revision was early notification of all teams involved in the care including physicians, nursing staff including laboratory and sterile processing. Another goal was a simplified classification scheme of potentially infected tissue. Tissues were divided into three categories depending on their risk of infectivity: high, low, and no detectable infectivity (Table 2). Only single use or disposable instruments are recommended for suspected cases who undergo surgery or invasive procedures involving contact with other than "no-risk" tissues. Non-disposable instruments or durable medical equipment that contact other than no risk tissues should be quarantined for possible decommissioning with appropriate labeling. All instruments are considered potentially contaminated when used on patients with conditions not clearly diagnosed before the procedure, and those instruments are either reprocessed according to prion guidelines or quarantined until the diagnosis is confirmed.

Table 2: Infectivity of Specific Types of Tissue				
	Classic/ Sporadic CJD	Variant CJD	Reprocessing	
High	Brain (including dura mater)	Brain (including dura mater)	NO	
Infectivity	Spinal cord	Spinal cord, spinal ganglia	reprocessing	
Tissue	Posterior eye	Posterior eye	allowed*	
	Pituitary tissue	Pituitary tissue		
		Trigeminal ganglia		
Low	Cerebrospinal fluid (CSF)	Adrenal gland	NO	
Infectivity	Liver	Blood	reprocessing	
Tissue	Lymph node	Tonsils (Laryngoscope)	allowed*	
	Kidney	Cerebrospinal fluid (CSF)		
	Lung (Bronchoscope)	Intestine (Endoscope)		
	Spleen	Bone marrow		
	Placenta	Liver		
	Olfactory epithelium	Lymph node		
		Kidney		
		Lung (Bronchoscope)		
		Spleen		
		Skeletal muscle		
		Placenta		
		Olfactory epithelium		
		Peripheral nerves		
		Rectum (Endoscope)		
Tissue with no	Peripheral nerve	Thyroid gland	OK to reprocess	
detectable	Intestine	Heart		
infectivity	Bone marrow	Adipose tissue		
	Whole blood, leukocytes,	Gingiva		
	serum, and plasma	Prostate and testis		
	Thyroid gland	Tears, sweat, saliva, and		
	Adrenal gland	sputum		
	Heart	Urine and feces		
	Skeletal muscle	Semen and vaginal		
	Adipose tissue	secretions		
	Gingiva	Breast milk		
	Prostate and testis			
	Tears, sweat, saliva, and			
	sputum			
	Urine and feces			
	Semen and vaginal			
	secretions			
	Breast milk			
Note: *Applies to surgical instruments and certain invasive equipment such as endoscopes and				
laryngoscope blades				

## Results

During the two-year retrospective review there were an annual average of 13 requests for processing spinal fluid for CJD. The average annual number of such patients for the two-year prospective follow-up surveillance after the intervention was 25. During that follow-up period no

similar incidents or other near misses. Specifically, there was no incorrect reprocessing of instruments or inadvertent re-use of durable equipment that was potentially contaminated. In response to queries from other IPs and epidemiologists, the policy was shared with hospitals outside of the network. Feedback was uniformly positive.

### Discussion

TSEs present diagnostic, infection control and patient notification challenges. Most clinicians are unfamiliar with TSEs due to the rarity of those diseases. vCJD and CJD can be hard to distinguish clinically. No gold standard laboratory test exists for differentiating types of TSEs. The turn-around-time for RT-QuIC can be up to 14 days or longer. In some cases, definitive diagnosis requires brain biopsy or only becomes available after autopsy. Last, the National Prion Center typically only releases autopsy results to public health departments, furthering diagnostic delay.

This approach could be criticized for not being warranted or justifiable due to the fact vCJD is extraordinarily uncommon. Even though sCJD is far more common than vCJD in the U.S., patients with suspected vCJD have been increasingly encountered in our health system. The suspicion was based on epidemiologic exposures and symptoms or signs consistent with vCJD. For example, having lived in the United Kingdom or France for several years or decades, or occupational exposure as taxidermists or abattoirs, or regular consumption of animal brains or cervid meat products. Furthermore, available data indicate that the incidence of CJD in cervids is increasing, and the potential exists for transmission to humans and subsequent human disease, and the species barrier is not static.<sup>7</sup> These occurrences are unlikely to be unique to our healthcare system. To that end, we make our policy to those interested. It is available from the corresponding author upon request.

## **Conflicts of Interest**

None

## **Funding Source**

None

## References

- 1. American Red Cross. Eligibility reference material. Available at: <u>https://www.redcrossblood.org/donate-blood/how-to-donate/eligibility-</u> <u>requirements/eligibility-criteria-alphabetical/eligibility-reference-material.html.</u> Dated 2021. Accessed January 19, 2021.
- 2. Belay ED, Schonberger LB. The public health impact of prion diseases. *Annu Rev Public Health* 2005; 26:191-212.
- 3. Ricketts MN, Cashman NR, Stratton EE, El Saadany S. Is Creutzfeldt-Jakob disease transmitted in blood? *Emerg Infect Dis.* 1997; 3:155-163.
- 4. Rutala WA, Weber DJ. Creutzfeldt-Jakob disease: recommendations for disinfection and sterilization. *Clin Infect Dis.* 2001; 32:1348-1356.
- 5. Rutala WA, Weber DJ; Society for Healthcare Epidemiology of America. Guideline for disinfection and sterilization of prion-contaminated medical instruments. *Infect Control Hosp Epidemiol*. 2010; 31:107-117.
- 6. Maheshwari A, Fischer M, Gambetti P, et al. Recent US case of variant Creutzfeldt-Jakob Disease global implications. *Emerg Infect Dis.* 2015; 21:50-759.
- 7. Osterholm MT, Anderson CJ, Zabel MD, Scheftel JM, Moore KA, Appleby BS. Chronic wasting disease in cervids: implications for prion transmission to humans and other animal species. *mBio*. 2019;10:e01091-19.
- 8. Diack AB, Will RG, Manson JC. Public health risks from subclinical variant CJD. *PLoS Pathog.* 2017; 13:e1006642.
- 9. Lesho EP, Clifford R, Vore K, et al. Sustainably reducing device utilization and devicerelated infections with DeCATHlons, device alternatives, and decision support. *Infect Control Hosp Epidemiol.* 2020; 41:1344-1347.
- 10. Advisory Committee on Dangerous Pathogens TSE Subgroup. ACDP's August 2016 Updated position statement on occurrence of vCJD and prevalence of infection in the UK. Available at: <u>https://www.gov.uk/government/groups/advisory-committee-on-dangerous-pathogens</u>. Accessed March 14, 2021.
- 11. World Health Organization. WHO infection control guidelines for transmissible spongiform encephalopathies. Report of a WHO consultation, Geneva, Switzerland, 23-26 March 1999. Available at:

https://www.who.int/csr/resources/publications/bse/WHO\_CDS\_CSR\_APH\_2000\_3/en/. Accessed March 14, 2021.